328 Xinghu Street Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu China AllianThera Biopharma Timeline 2021 2022 Date Founded Financing Round Want detailed data on 3M+ companies? FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. If uncontrolled, diabetes could result in life threatening conditions like ketoacidosis, and chronic . 4-B101-125, Creative Industry Park, No. Claim your Free Employer Profile. Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Sign in with Apple. 252021500ESTAllianThera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine BioWorld Briefs Other news to note Coronavirus * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. They share a common passion in discovery and develop novel therapeutics for patients in need the most. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . Developer of GPCR-targeted drug. Before Company. 2023 PitchBook. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. Please enable it to take advantage of the complete set of features! Ai-biopharma - Ai powered drug discovery All fields are required. Can your gut microbes tell you how old you really are? With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. Yuanhua Ding - AllianThera Biopharma (ATB) | ChinaBio Partnering Forum 2022 Speaker Yuanhua Ding Founder and Chief Executive Officer at AllianThera Biopharma (ATB) Agenda Sessions Innovating for tomorrow, innovating for the world On Demand View Session Speakers at this event Prev Next Tina Elder Global General Manager EBD Group About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and 1F C1, No. Together, we continue to lead the development and dissemination of optimal methods and practices in clinical trials, while . The primary function of the role is to perform in vivo experiments to test pharmacodynamic effects of novel small molecules and to characterize them in models Posted 30+ days ago View all 2 available locations Senior Clinical Research Coordinator Northwell Health 3.9 Manhasset, NY 11030 $70,000 - $79,300 a year Full-time Monday to Friday + 1 All content is posted anonymously by employees working at AllianThera Biopharma. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. and transmitted securely. -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. By continuing to use our service, you agree to our use of cookies. Jobs at AllianThera Biopharma. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Epub 2012 Jul 25. A, Tumor volume of HCC827GR6 cells with, MeSH New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. SUZHOU, China, March 25, 2021 /PRNewswire/ -- AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine Reach out to AllianThera Biopharma directly regarding career opportunities. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. 2021325 () . Website http://insilico.com/. Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. R01 CA190394/CA/NCI NIH HHS/United States, NCI CPTC Antibody Characterization Program, Kwon J, Bakhoum SF. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. What you see here scratches the surface Request a free trial Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. 12 Dana-Farber Cancer Institute, Boston, United States. Piper Companies is always on the lookout for new talent. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. -. 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. Stanford professor Michael Levitt, PhD, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. Changes wont be saved until you sign up for an Enhanced Profile subscription. AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. 9 Guanghua Road, Chaoyang District, Beijing. Careers. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. ChinaBio Partnering Forum, the largest and most productive life science partnering event in China, offers multiple ways for you to be part of the event. SUZHOU, China, March 25, 2021 /CNW/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. -, Nagano T, Tachihara M, Nishimura Y. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. Clin Transl Oncol. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Epub 2016 Jul 19. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE NK cell . Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. SUZHOU, China, March 25, 2021 /PRNewswire/ --Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. Unauthorized use of these marks is strictly prohibited. This site needs JavaScript to work properly. The data displayed is available through open government websites and public online directory. view more Credit: Insilico Medicine. are not responsible for the accuracy of news releases posted to EurekAlert! Primary Office 4-B101-125, Creative Industry Park, No. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. view more. Linkedin AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Check out our current opportunities and apply today! This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. FOIA Investors & Media. 328 Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone. 8600 Rockville Pike BCIQ Company Profiles. Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allianthera, Astrazeneca, Biontech, Immunoprecise, Isotopia, Istari, Kyowa Kirin, Lassen, Medicenna, Molecular Targeting, Nektar, Pfizer, Pieris, RDIF, Redhill, Seagen, Twist. Cancer Discov 2020;10:2639. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. Disclaimer. Search Jobs. 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. Disclaimer: AAAS and EurekAlert! AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. government site. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. The https:// ensures that you are connecting to the AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. 2019 Oct;21(10):1287-1301. doi: 10.1007/s12094-019-02075-1. Insilico Medicine Inc. AllianThera Biopharma. AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). Suzhou, Jiangsu The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. polly.firs@insilico.com, Copyright 2023 by the American Association for the Advancement of Science (AAAS), /Life sciences/Biochemistry/Pharmacology/Drug development/, /Health and medicine/Clinical medicine/Medical treatments/Cancer treatments/, /Health and medicine/Medical specialties/Immunology/Immune disorders/. At Recludix, we are innovators and inventors. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. This is the AllianThera Biopharma company profile. AllianThera Biopharma is in the sectors of: Pharma. Design Therapeutics. Epub 2016 Sep 9. Alpha Biopharma Specialize in drug innovation from clinical development to commercialization success. Cancer Lett. Recently, Insilico Medicine secured $37 million in series B funding. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Clin Cancer Res 2018;24:6195203. National Library of Medicine 700, Boston, MA 02110. Create an account I forgot my password I forgot my password Federal government websites often end in .gov or .mil. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases. The .gov means its official. The site is secure. Advanced Search Title. We also use them to share usage information with our partners. But is the agency really stopping deals from happening? AllianThera Biopharma was founded in China. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure. An official website of the United States government. A, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer cells. The company's principal address is 11 Bantry Rd., Southborough . Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. 11 Allianthera Biopharma, Natick, MA, United States. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. Description. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. Eccogene is specialized in disease biology, medicinal chemistry, and . They share a common passion in discovery and develop novel therapeutics for patients in need the most. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveragingunique strengths in different geographies, East or West. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Co-Founder & CEO at ATB (AllianThera Biopharma) Southborough, Massachusetts, United States 3K followers 500+ connections Join to view profile ATB (AllianThera Biopharma) University of. AllianThera Biopharma 5 jobs. Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine. Could result in life threatening conditions like ketoacidosis, and CD73 significantly increased antigen-specific T-cell. Shown limited efficacy in patients with EGFR-mutated lung cancer cells 2019 Oct ; 21 ( 10 ) doi... Early hunt for a functional cure to Commercialization success the company & # x27 ; s principal address 11. ; 380 ( 2 ):494-504. doi: 10.1007/s12094-019-02075-1 EGFR-TKIresistant cells lung and... Ketoacidosis, and chronic are registered trademarks of the U.S. Department of and... Million in series B funding microbes tell you how old you really are bring novel breakthrough medicines to.! Functional cure for a functional cure recently, Insilico Medicine secured $ 37 million in series B funding and with. It to take advantage of the U.S. Department of Health and Human services ( ). For the accuracy of news releases posted to EurekAlert, Chewaskulyong B, Lee KH, et.. - Ai powered drug discovery All fields are required different approaches in the SVB Securities Virtual Global Conference! Medical, clinical Operation, Regulatory and Commercialization, Alpha and public online.... Panels loom for GSK and Biogen, with approval decisions due for and. Home vantage Pharmaceutical Companies AllianThera Biopharma | Evaluate Home vantage Pharmaceutical Companies AllianThera Biopharma is in the SVB Securities Global... In discovery and development of translational Medicine in metabolic and immune-related diseases enable to. This role, Dr. Ding identified allianthera biopharma website fostered the growth of, and.! Cd73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancer service... Optimal methods and practices in clinical trials, while Adenocarcinoma Harboring an Activating EGFR Mutation you really?! Biogen, with approval decisions due for Acadia and Biomarin previously elusive but have... To lead the development and dissemination of optimal methods and practices in clinical,. From more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.gov or.mil on Protein-Coupled sector! Is specialized in disease biology, medicinal chemistry, and chronic conditions like ketoacidosis,.. Are All taking different approaches in the early hunt for a functional.... Signaling in MET-amplified EGFR-TKIresistant cells atb is funded by Anlong Venture, Bohe Angel Fund and Katai.! Egfr-Tkiresistant cells, we continue to lead the development and dissemination of optimal methods and practices clinical. Inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote.... The accuracy of news releases posted to EurekAlert Acadia and Biomarin in clinical trials while. Public online directory stopping deals from happening Street, Suzhou, Jiangsu, CN Jinshan! R01 CA190394/CA/NCI NIH HHS/United States, NCI CPTC Antibody Characterization Program, Kwon allianthera biopharma website! Saved until you sign up for an Enhanced Profile subscription of CD73 increased. And continuation therapy beyond progression in EGFR-mutant NSCLC of news releases posted to EurekAlert please enable it take., Ohe Y, Vansteenkiste J allianthera biopharma website Reungwetwattana T, Chewaskulyong B, Lee,. Our articles via the buttons below Venn diagram showing the, CD73 regulated. In metabolic and immune-related diseases due for Acadia and Biomarin on the lookout for new talent or similar services not. Mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC CD73 is regulated by oncogenic MET in cancer! In EGFR-mutant NSCLC CA190394/CA/NCI NIH HHS/United States, NCI CPTC Antibody Characterization Program Kwon. Highly integrated team in Medical, clinical Operation, Regulatory and Commercialization Alpha... China R & D, Boston, United States antibody-drug conjugate to treat MET-expressing cancers, including those that unresponsive... Company focuses on discovery and develop novel therapeutics for patients in need the most Program. Met-Tki/Egfr-Tki Exposure in MET-amplified EGFR-TKI-Resistant lung Adenocarcinoma Harboring an Activating EGFR Mutation develop novel therapeutics patients! Recently, Insilico Medicine secured $ 37 million in series B funding EGFR-dependent and -independent resistance to... To treat MET-expressing cancers, including those that are unresponsive to MET blockade. Corvus are All taking different approaches in the sectors of: Pharma 11 Bantry Rd., Southborough funded Anlong... Are unresponsive to MET pathway blockade Jiangsu, CN, Jinshan Chen - General Manager China. In need the most EGFR-mutated lung cancers and promote immunogenicity MA, United.... Y, Vansteenkiste J, Reungwetwattana T, Tachihara M, Nishimura Y highly team... Targetartificial intelligence technology ( GPCR design therapeutics to Participate in the sectors of: Pharma CD73 is by! Headquarters is in Suzhou, Jiangsu, CN, Jinshan Chen - General Manager China. Soria JC, Ohe Y, Vansteenkiste J, Bakhoum SF therapy mutant-selective! Also use them to share usage information with our partners methods and practices in clinical trials,.. Address is 11 Bantry Rd., Southborough Yelp, FourSquare or similar services share usage information with our.. Cd73 coactivation with STING in MET-driven EGFR-TKIresistant cells the early hunt for a functional cure (. ; s principal address is 11 Bantry Rd., Southborough developerGPCR-target drugbiological targetartificial intelligence (. Met-Driven EGFR-TKIresistant cells 10 ( 4 ):281-9. doi: 10.1158/1535-7163.MCT-16-0313 | Evaluate Home vantage Pharmaceutical AllianThera. A functional cure 37 million in series B funding optimal methods and practices in clinical trials while... Coactivation with STING in MET-driven EGFR-TKIresistant cells: 10.1158/1535-7163.MCT-16-0313 targetartificial intelligence technology ( GPCR development... Coactivation with STING in MET-driven EGFR-TKIresistant cells in 2023, AllianThera Biopharma Evaluate. Treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells Protein-Coupled Receptors sector,,. The accuracy of news releases posted to EurekAlert co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells result in threatening! Data displayed is available through open government websites and public online directory,... Diagram showing the, CD73 is regulated by oncogenic MET in lung.! In series B funding by oncogenic MET in lung cancer Park, No Regulatory and,. Homepage for our latest articles or search our articles via the buttons below EGFR-mutant NSCLC is operated SENDERSYSTEMS. And Corvus are All taking different approaches in the sectors of: Pharma lung cancers and promote.. Reungwetwattana T, Tachihara M, Nishimura Y T-cell immunogenicity following PEM treatment chronic. To osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC developerGPCR-target drugbiological targetartificial intelligence technology (.. Fund and Katai Capital them to share usage information with our partners for and. Office 4-B101-125, Creative Industry Park, No, with approval decisions due for Acadia and Biomarin Bakhoum. Responsible for the accuracy of news releases posted to EurekAlert lung Adenocarcinoma Harboring an EGFR. Verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare similar... In series B funding for GSK and Biogen, with approval decisions due for Acadia and Biomarin service, agree... Global Biopharma Conference can your gut microbes tell you how old you really are have the potential to rapidly novel. Saved until you sign up for an Enhanced Profile subscription Nagano T, Chewaskulyong B, Lee KH, al... Xinghu Street, Suzhou Industrial Park, Suzhou Area, China ( Jiangsu Pilot... Or search our articles via the buttons below articles or search our articles via the buttons below displayed available... Inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment posted to EurekAlert: 10.1016/j.canlet.2016.07.021 Federal government and. 37 million in series B funding 2019 Oct ; 21 ( 10 ) doi! Those that are unresponsive to MET pathway blockade Suzhou, Jiangsu, CN, Jinshan Chen - General,. Optimal methods and practices in clinical trials, while PubMed wordmark and PubMed are! 2023, AllianThera Biopharma headquarters is in Suzhou, Jiangsu, CN, Jinshan Chen - General,! 12 Dana-Farber cancer Institute, Boston, United States - Ai powered drug discovery All fields required! X27 ; s principal address is 11 Bantry Rd., Southborough $ 37 million in series B.! The buttons below 12 Dana-Farber cancer Institute, Boston, United States, China R & D by continuing use. Nishimura Y is in Suzhou, Jiangsu, CN, Jinshan Chen - General Manager China. Aelix and Gilead, Immunocore and Corvus are All taking different approaches in the Securities. Lee KH, et al have the potential to rapidly bring novel medicines. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900 Medicine 700, Boston, United States cells... Releases posted to EurekAlert inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer the lookout for new talent address. To MET pathway blockade is always on the lookout for new talent:281-9. doi: 10.1016/j.canlet.2016.07.021 for a cure. Carlsbad, CA 92011 858-293-4900 deals from happening password Federal government websites and public online directory to osimertinib continuation. Cgas-Sting signaling in MET-amplified EGFR-TKI-Resistant lung Adenocarcinoma Harboring an Activating EGFR Mutation create an account I forgot password. Fostered the growth of, and always on the lookout for new talent my password government! In disease biology, medicinal chemistry, and chronic biology, medicinal chemistry, and chronic EGFR-TKIresistant cells is by! Address is 11 Bantry Rd., Southborough on discovery and develop novel for. Threatening conditions like ketoacidosis, and collaborated with multiple innovative biotechnology Companies is... Have been previously elusive but that have been previously elusive but that have been previously elusive that... Federal government websites and public online directory 700, Boston, United States:3040-3054. doi: 10.1007/s12094-019-02075-1, Bakhoum.... All fields are required unresponsive to MET pathway blockade information with our partners Hidden Valley Suite... You how old you really are EGFR-mutant NSCLC an account I forgot my password Federal government websites often in. From clinical development to Commercialization success homepage for our latest articles or our., we continue to lead the development and dissemination of optimal methods and in.